FRANCINI, EDOARDO
FRANCINI, EDOARDO
Medicina Sperimentale e Clinica
1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
2019 Correale, P; Staropoli, N; Pastina, P; Giannicola, R; Botta, C; Francini, E; Ridolfi, L; Mini, E; Ciliberto, D; Agostino, R M; Strangio, A; Azzarello, D; Nardone, V; Falzea, A; Tassone, P; Giordano, A; Pirtoli, L; Francini, G; Tagliaferri, P S
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient
2020 Miano S.T.; Francini E.; Petrioli R.; Francini G.
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer
2014 Francini E; Fiaschi AI; Petrioli R; Francini F; Bianco V; Perrella A; Paganini G; Laera L; Roviello G
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival
2015 Francini E; Fiaschi AI; Petrioli R; Bianco V; Laera L; Francini F; Roviello G
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer
2015 Roviello Giandomenico; Francini Edoardo; Perrella Armando; Laera Letizia; Mazzei Maria Antonietta; Guerrini Susanna; Petrioli Roberto
Association of concomitant bone resorption inhibitors with overall survival among patients with metastatic castration-resistant prostate cancer and bone metastases receiving abiraterone acetate with prednisone as first-line therapy.
2021 Francini E, Montagnani F, Nuzzo PV, Gonzalez-Velez M, Alimohamed NS, Rosellini P, Moreno-Candilejo I, Cigliola A, Rubio-Perez J, Crivelli F, Shaw GK, Zhang L, Petrioli R, Bengala C, Francini G, Garcia-Foncillas J, Sweeney CJ, Higano CS, Bryce AH, Harshman LC, Lee-Ying R, Heng DYC.
Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival
2023 Gambale, Elisabetta; Palmieri, Valeria Emma; Rossi, Virginia; Francini, Edoardo; Bonato, Adele; Salfi, Alessia; Galli, Luca; Mela, Marinella Micol; Pillozzi, Serena; Antonuzzo, Lorenzo
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases
2021 McGregor B.; Zhang L.; Gray K.P.; Shaw G.; Evan C.; Francini E.; Sweeney C.
Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases
2018 Zhang, L; Gray, KP; Shaw, G; Evan, C; Francini, E; Sweeney, C
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer
2018 Petrioli R.; Francini E.; Cherri S.; Torre P.; Fiaschi A.I.; Miano S.T.; Marrelli D.; Rovello F.; Francini G.
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study
2015 Petrioli R; Roviello G; Fiaschi AI; Laera L; Miano ST; Bianco V; Francini E
CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ)
2020 Francini, Edoardo; Ou, Fang-Shu; Lazzi, Stefano; Petrioli, Roberto; Multari, Andrea Giovanni; Pesola, Guido; Messuti, Luciana; Colombo, Elena; Livellara, Virginia; Bazzurri, Serena; Cherri, Sara; Salvatora, Miano; Wolfe, Eric; Alberts, Steven R; Hubbard, Joleen Marie; Yoon, Harry H.; Francini, Guido
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab
2012 Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G; Multidisciplinary Oncology Group On Gastrointestinal Tumors
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer.
2021 Francini E, Ou FS, Rhoades J, Wolfe EG, O'Connor EP, Ha G, Gydush G, Kelleher KM, Bhatt RS, Balk SP, Sweeney CJ, Adalsteinsson VA, Taplin ME, Choudhury AD.
Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine
2022 Francini, Edoardo; Fanelli, Giuseppe Nicolò; Pederzoli, Filippo; Spisak, Sandor; Minonne, Erika; Raffo, Massimiliano; Pakula, Hubert; Tisza, Viktoria; Scatena, Cristian; Naccarato, Antonio Giuseppe; Loda, Massimo; Nuzzo, Pier Vitale
Circulating free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).
2020 Edoardo Francini
Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC)
2020 Edoardo Francini; Fang-Shu Ou; Justin Rhoades; Eric G. Wolfe; Edward O'Connor; Gavin Ha; Gydush Gregory; Kaitlin Kelleher; Rupal Satish Bhatt; Steven P. Balk; Christopher Sweeney; Viktor Adalsteinsson; Mary-Ellen Taplin; Atish Dipankar Choudhury
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience
2015 Petrioli, Roberto; Roviello, Giandomenico; Laera, Letizia; Luzzi, Luca; Paladini, Piero; Ghiribelli, Claudia; Voltolini, Luca; Martellucci, Ignazio; Bianco, Vincenzo; Francini, Edoardo
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
2023 Nuzzo, Pier Vitale; Pederzoli, Filippo; Saieva, Calogero; Zanardi, Elisa; Fotia, Giuseppe; Malgeri, Andrea; Rossetti, Sabrina; Valenca Bueno, Loana; Andrade, Livia Maria Q S; Patrikidou, Anna; Mestre, Ricardo Pereira; Modesti, Mikol; Pignata, Sandro; Procopio, Giuseppe; Fornarini, Giuseppe; De Giorgi, Ugo; Russo, Antonio; Francini, Edoardo
Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study
2023 Lee-Ying, Richard M.; Saieva, Calogero; Nuzzo, Pier Vitale; Malgeri, Andrea; Fotia, Giuseppe; Zanardi, Elisa; Rossetti, Sabrina; Valenca, Loana Bueno; Patrikidou, Anna; Modesti, Mikol; Martins Oliveira, Thiago; Pignata, Sandro; Fornarini, Giuseppe; Procopio, Giuseppe; Santini, Daniele; Sweeney, Christopher; Heng, Daniel Yick Chin; De Giorgi, Ugo; Russo, Antonio; Francini, Edoardo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis | 2019 | Correale, P; Staropoli, N; Pastina, P; Giannicola, R; Botta, C; Francini, E; Ridolfi, L; Mini, E; Ciliberto, D; Agostino, R M; Strangio, A; Azzarello, D; Nardone, V; Falzea, A; Tassone, P; Giordano, A; Pirtoli, L; Francini, G; Tagliaferri, P S | |
| A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient | 2020 | Miano S.T.; Francini E.; Petrioli R.; Francini G. | |
| Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer | 2014 | Francini E; Fiaschi AI; Petrioli R; Francini F; Bianco V; Perrella A; Paganini G; Laera L; Roviello G | |
| Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival | 2015 | Francini E; Fiaschi AI; Petrioli R; Bianco V; Laera L; Francini F; Roviello G | |
| An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer | 2015 | Roviello Giandomenico; Francini Edoardo; Perrella Armando; Laera Letizia; Mazzei Maria Antonietta; Guerrini Susanna; Petrioli Roberto | |
| Association of concomitant bone resorption inhibitors with overall survival among patients with metastatic castration-resistant prostate cancer and bone metastases receiving abiraterone acetate with prednisone as first-line therapy. | 2021 | Francini E, Montagnani F, Nuzzo PV, Gonzalez-Velez M, Alimohamed NS, Rosellini P, Moreno-Candilejo I, Cigliola A, Rubio-Perez J, Crivelli F, Shaw GK, Zhang L, Petrioli R, Bengala C, Francini G, Garcia-Foncillas J, Sweeney CJ, Higano CS, Bryce AH, Harshman LC, Lee-Ying R, Heng DYC. | |
| Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival | 2023 | Gambale, Elisabetta; Palmieri, Valeria Emma; Rossi, Virginia; Francini, Edoardo; Bonato, Adele; Salfi, Alessia; Galli, Luca; Mela, Marinella Micol; Pillozzi, Serena; Antonuzzo, Lorenzo | |
| Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases | 2021 | McGregor B.; Zhang L.; Gray K.P.; Shaw G.; Evan C.; Francini E.; Sweeney C. | |
| Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases | 2018 | Zhang, L; Gray, KP; Shaw, G; Evan, C; Francini, E; Sweeney, C | |
| Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer | 2018 | Petrioli R.; Francini E.; Cherri S.; Torre P.; Fiaschi A.I.; Miano S.T.; Marrelli D.; Rovello F.; Francini G. | |
| Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study | 2015 | Petrioli R; Roviello G; Fiaschi AI; Laera L; Miano ST; Bianco V; Francini E | |
| CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ) | 2020 | Francini, Edoardo; Ou, Fang-Shu; Lazzi, Stefano; Petrioli, Roberto; Multari, Andrea Giovanni; Pesola, Guido; Messuti, Luciana; Colombo, Elena; Livellara, Virginia; Bazzurri, Serena; Cherri, Sara; Salvatora, Miano; Wolfe, Eric; Alberts, Steven R; Hubbard, Joleen Marie; Yoon, Harry H.; Francini, Guido | |
| CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab | 2012 | Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G; Multidisciplinary Oncology Group On Gastrointestinal Tumors | |
| Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. | 2021 | Francini E, Ou FS, Rhoades J, Wolfe EG, O'Connor EP, Ha G, Gydush G, Kelleher KM, Bhatt RS, Balk SP, Sweeney CJ, Adalsteinsson VA, Taplin ME, Choudhury AD. | |
| Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine | 2022 | Francini, Edoardo; Fanelli, Giuseppe Nicolò; Pederzoli, Filippo; Spisak, Sandor; Minonne, Erika; Raffo, Massimiliano; Pakula, Hubert; Tisza, Viktoria; Scatena, Cristian; Naccarato, Antonio Giuseppe; Loda, Massimo; Nuzzo, Pier Vitale | |
| Circulating free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). | 2020 | Edoardo Francini | |
| Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC) | 2020 | Edoardo Francini; Fang-Shu Ou; Justin Rhoades; Eric G. Wolfe; Edward O'Connor; Gavin Ha; Gydush Gregory; Kaitlin Kelleher; Rupal Satish Bhatt; Steven P. Balk; Christopher Sweeney; Viktor Adalsteinsson; Mary-Ellen Taplin; Atish Dipankar Choudhury | |
| Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience | 2015 | Petrioli, Roberto; Roviello, Giandomenico; Laera, Letizia; Luzzi, Luca; Paladini, Piero; Ghiribelli, Claudia; Voltolini, Luca; Martellucci, Ignazio; Bianco, Vincenzo; Francini, Edoardo | |
| Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer | 2023 | Nuzzo, Pier Vitale; Pederzoli, Filippo; Saieva, Calogero; Zanardi, Elisa; Fotia, Giuseppe; Malgeri, Andrea; Rossetti, Sabrina; Valenca Bueno, Loana; Andrade, Livia Maria Q S; Patrikidou, Anna; Mestre, Ricardo Pereira; Modesti, Mikol; Pignata, Sandro; Procopio, Giuseppe; Fornarini, Giuseppe; De Giorgi, Ugo; Russo, Antonio; Francini, Edoardo | |
| Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study | 2023 | Lee-Ying, Richard M.; Saieva, Calogero; Nuzzo, Pier Vitale; Malgeri, Andrea; Fotia, Giuseppe; Zanardi, Elisa; Rossetti, Sabrina; Valenca, Loana Bueno; Patrikidou, Anna; Modesti, Mikol; Martins Oliveira, Thiago; Pignata, Sandro; Fornarini, Giuseppe; Procopio, Giuseppe; Santini, Daniele; Sweeney, Christopher; Heng, Daniel Yick Chin; De Giorgi, Ugo; Russo, Antonio; Francini, Edoardo |